COVID-19 in the Developing World: Is the Immune Response to α-Gal an Overlooked Factor Mitigating the Severity of Infection?
- 12 November 2020
- journal article
- editorial
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 6 (12) , 3104-3108
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which has affected millions of people worldwide. Considerably lower prevalence and fatality rates resulting from COVID-19 are reported in Africa and Asia than in the industrialized world. In this Viewpoint, we discuss the possibility that this intriguing phenomenon could be, among other factors, due to protective immunity of the oligosaccharide galactose-α-1,3-galactose (α-Gal). The α-Gal immunity induced by gut microbiota that express the same glycan modification may prevent COVID-19 through the activation of different mechanisms involved in SARS-CoV-2 neutralization and the downregulation of the inflammatory response in the lungs of infected patients.Keywords
Funding Information
- Consejería de Educación, Cultura y Deportes, Junta de Comunidades de Castilla-La Mancha (CCM17-PIC-036 / SBPLY/17/180501/000185)
This publication has 30 references indexed in Scilit:
- Effect of blood type on anti-α-Gal immunity and the incidence of infectious diseasesExperimental & Molecular Medicine, 2017
- Gut Microbiota Elicits a Protective Immune Response against Malaria TransmissionCell, 2014
- IgE Production to α-Gal Is Accompanied by Elevated Levels of Specific IgG1 Antibodies and Low Amounts of IgE to Blood Group BPLOS ONE, 2013
- Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibodyVaccine, 2009
- Expression of ABO or related antigenic carbohydrates on viral envelopes leads to neutralization in the presence of serum containing specific natural antibodies and complementBlood, 2002
- Quantitation and characterization of anti‐Galα1–3Gal antibodies in sera of 200 healthy personsXenotransplantation, 1999
- A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody.Journal of Experimental Medicine, 1995
- Variations in Activity of the Human Natural Anti-Gal Antibody in Young and Elderly PopulationsThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 1995
- Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells.Journal of Biological Chemistry, 1988
- The human natural anti-Gal IgG. III. The subtlety of immune tolerance in man as demonstrated by crossreactivity between natural anti-Gal and anti-B antibodies.Journal of Experimental Medicine, 1987